Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Think Research Corporation
V.THNK
Healthcare
Medical Devices
Think Research Corporation is a Canada-based company that offers digital health software solutions. It is a provider of cloud-based data, knowledge, and software solutions primarily delivered as software-as-a-service (SaaS) to healthcare delivery systems and the practitioners that they support. Its operations are organized into three lines of business: Software and Data Solutions, Clinical...
Research, and Clinical Services. Its SaaS solutions help patients find, navigate, and connect to health services across large governments and payer clients, while also ensuring safety for prescribed medications at pharmacies. Through its wholly owned subsidiary, BioPharma Services Inc., the Company provides research data and analysis derived from Phase I clinical trials, bioequivalence studies and bioanalytical services. Its clinics act as a test bed for its software and technology, transforming them with digital solutions that optimize clinical outcomes, streamline workflows, and optimize billing.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
TSXV:THNK - Post Discussion
Think Research Corporation
> Echelon Target $3.40.
New Post
View:
Discussion
List
(4)
•••
KerBer
X
View Profile
View Bullboard History
Post by
KerBer
on Apr 27, 2022 9:19pm
Echelon Target $3.40.
https://www.cantechletter.com/2022/04/133353/
(1935)
•••
Possibleidiot01
X
View Profile
View Bullboard History
Comment by
Possibleidiot01
on Apr 28, 2022 6:05am
Think Research is undervalued, Echelon says (April, 2022) By Jayson MacLean Published on April 27, 2022 Last Updated on April 27, 2022 Filed under: All posts, Analysts, Health Stock: thnk Echelon Capital Markets analyst Rob Goff sees a big market disconnect on Think Research Corp. (Think Research Stock
...more
(18)
•••
dt_core
X
View Profile
View Bullboard History
Comment by
dt_core
on May 07, 2022 4:06pm
It looks like most 12 month target prices for the company range from $2.00 to $2.90 now. That's down a bit as analysts adjusted their models for higher discount rates now being reflected more generally in the markets. Very few analysts adjusted their fundamental targets for the company. As an aside, with the stock now trading where it is we're seeing some implications of the poor capital
...more
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
One Property, One Focus on Advancing this Gold Project in Ontario
Options Trading for Retiring: Key Strategies in Balancing Retirement Income